This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802. During this extension study, all patients will receive open-label treatment of octreotide acetate in microspheres every 4 weeks for 2 years for the treatment of moderately severe to severe NPDR and low risk PDR.

Inclusion Criteria:

• written informed consent provided prior to participation in the extension study
• successful completion of study CSMS995 0802
• willingness to comply with all study requirements

Exclusion Criteria:

• more than 8 weeks interval since the completion of study CSMS995 0802
• premature discontinuation from study CSMS995 0802

Other protocol-defined inclusion/exclusion criteria may apply.